Chemotherapy has been shown to prolong the survival of patients with stage III non-small cell lung cancer. In particular, cisplatin and vinblastine administered before definitive radiotherapy results in a significant prolongation of median survival and increases the 2-year survival rate. Concomitant chemoradiotherapy also holds promise. Recently, several new active agents and combinations have been described for the treatment of stage III disease. The integration of these drugs and novel regimens into treatment plans for stage III non-small cell lung cancer is of great interest and a focus of current clinical investigations. Early data from these clinical trials are reviewed here.